Management of Bell’s Palsy in Adults (AAO‑HNS Guidelines)

Primary Pharmacologic Therapy

• The American Academy of Otolaryngology–Head and Neck Surgery (AAO‑HNS) recommends that all patients ≥ 16 years receive oral corticosteroids within 72 hours of symptom onset, as this is the only treatment with strong evidence for improving facial‑nerve recovery. 1, 2 Strength: Strong.
• High‑dose oral corticosteroids initiated within the 72‑hour window constitute the cornerstone of therapy. Recommended regimens include:
  
  • Prednisolone 50–60 mg once daily for 5 days, then taper over 5 days (10‑day total course), or
  • Prednisolone 25 mg twice daily for 10 days. 1, 2 Strength: Moderate (based on trial protocols).
• Clinical trial data show 83 % facial‑nerve recovery at 3 months with prednisolone versus 63.6 % with placebo (p < 0.001). 1, 2 Strength: High (statistically significant).
• At 9 months, recovery rates were 94.4 % with prednisolone versus 81.6 % with placebo. 1, 2 Strength: High.
• Steroid‑treated patients experience a significantly shorter time to recovery compared with placebo. 1, 2 Strength: High.

Antiviral Use

• Antiviral monotherapy is not recommended; it provides no benefit over placebo and is considered contraindicated. 1, 3, 4 Strength: Strong.
• Combination therapy (corticosteroids + antivirals) may be offered for patients with severe facial paralysis. Evidence from randomized trials shows 96.5 % recovery with combination therapy versus 89.7 % with steroids alone, indicating a modest benefit. 3 Strength: Moderate.

Ocular Protection

• The AAO‑HNS issues a strong recommendation for immediate eye protection in any patient with impaired eye closure to prevent corneal injury. 1, 5, 4 Strength: Strong.
• Recommended measures (all supported by the same evidence set):
  
  • Use of artificial tears during waking hours,
  • Application of lubricating ointment at night,
  • Eye patching or taping the eyelid closed during sleep. 1 Strength: Strong.

Timing of Treatment

• Treatment must be started within 72 hours of onset; benefits after this window are unclear and markedly reduced. 1, 2, 6, 4 Strength: Strong.

Special Populations

Children (< 16 years)

• Evidence regarding the efficacy of steroids in children is inconclusive; routine use cannot be strongly endorsed. 1, 3, 6 Strength: Low/uncertain.
• Steroids may be considered after shared decision‑making with caregivers, given a favorable benefit‑harm ratio in the limited data available. 1, 3 Strength: Moderate.

Pregnant Women

• (No cited evidence provided for specific recommendations; therefore omitted from the guideline summary.)

Diagnostic Approach

• Prior to initiating therapy, the AAO‑HNS advises a comprehensive history and physical examination to exclude alternative causes of facial paralysis (e.g., stroke, tumors, Lyme disease, sarcoidosis, herpes zoster). 1, 7, 5, 4 Strength: Strong.
• Routine laboratory testing, neuro‑imaging (MRI/CT), and electrodiagnostic studies are not recommended in cases of incomplete paralysis. 1, 4 Strength: Strong.

Interventions Lacking Sufficient Evidence

• Surgical facial‑nerve decompression – no recommendation can be made due to insufficient high‑quality evidence. 1, 8, 4 Strength: Insufficient.
• Acupuncture – not recommended; evidence is lacking. 1, 8, 4 Strength: Insufficient.
• Physical therapy – no formal recommendation; while it may help in severe cases, high‑quality data are absent. 1, 8, 4 Strength: Insufficient.

Follow‑up and Referral Criteria

• Re‑assessment or referral to a facial‑nerve specialist is advised if any new or worsening neurologic signs develop. 1, 5, 4 Strength: Strong.
• Prompt evaluation is required for new ocular symptoms (e.g., corneal irritation, decreased tear production). 1, 5, 4 Strength: Strong.
• Patients with incomplete facial recovery at 3 months after onset should be reassessed and possibly referred. 1, 5, 4 Strength: Strong.

Evidence‑Based Management of Bell’s Palsy

First‑Line Pharmacologic Therapy

• Oral corticosteroids should be started within 72 hours of symptom onset in all patients ≥ 16 years to improve facial‑nerve recovery and reduce long‑term disability. In a high‑quality trial, 83 % recovered at 3 months versus 63.6 % with placebo (p < 0.001), and 94.4 % recovered at 9 months versus 81.6 % with placebo; time to recovery was also significantly shorter. Strong evidence (AAO‑HNS) 9

Antiviral Therapy

• Antiviral agents alone do not improve outcomes compared with placebo and should not be used as monotherapy. No benefit (AAO‑HNS) 10
• Adding antivirals to steroids may be considered for patients with severe or complete facial paralysis; one trial showed 96.5 % recovery with combination therapy versus 89.7 % with steroids alone, representing a modest benefit. Evidence is limited and larger trials are lacking, but the low risk permits shared decision‑making. Modest benefit, uncertain (AAO‑HNS) 11

Ocular Protection

• Immediate eye‑protection measures are mandatory for any patient with impaired eyelid closure to prevent corneal abrasion, exposure keratopathy, and possible permanent vision loss. Essential recommendation (AAO‑HNS) 11

Special Populations

• Children (< 16 years): Current data are inconclusive and high‑quality trials are lacking; steroid therapy may be considered on the basis of presumed similar pathophysiology and a favorable benefit‑risk profile, with caregiver involvement in decision‑making. Inconclusive evidence (AAO‑HNS) 10

Diagnostic Approach

• Bell’s palsy is a diagnosis of exclusion. Typical features include rapid onset (< 72 h), unilateral facial weakness involving the forehead, and absence of other cranial‑nerve deficits. Routine laboratory tests, MRI/CT, or electrodiagnostic studies are not required in classic presentations. Strong recommendation (AAO‑HNS) [12][9]
• Red‑flag findings that warrant imaging: bilateral facial palsy, isolated branch palsy, additional cranial‑nerve involvement, recent trauma, or lack of any recovery after 3 months. Strong recommendation (AAO‑HNS) 9

Non‑Recommended Interventions

• Surgical facial‑nerve decompression: Evidence insufficient to support routine use. Insufficient evidence (AAO‑HNS) 12
• Acupuncture: Evidence insufficient to recommend. Insufficient evidence (AAO‑HNS) 12
• Physical therapy: No formal recommendation due to lack of high‑quality data; may be considered in severe cases. Insufficient evidence (AAO‑HNS) 12

Follow‑Up and Referral Criteria

• Refer to a facial‑nerve specialist or reassess if any of the following occur:

Prognosis

• Without treatment, about 70 % of patients with complete paralysis recover fully within 6 months; with incomplete paralysis, spontaneous recovery occurs in up to 94 % of cases.
• Consequently, up to 30 % of patients may have persistent deficits, supporting the need for early aggressive therapy. Most patients show some improvement within 2–3 weeks and achieve complete recovery by 3–4 months. Observational data (AAO‑HNS) 13

Evidence‑Based Management of Bell’s Palsy

Pharmacologic Treatment

• Oral corticosteroids should be given to all patients ≥ 16 years within 72 hours of symptom onset; this is the only therapy with strong evidence for improving facial‑nerve recovery (American Academy of Otolaryngology‑Head and Neck Surgery, Level A) 14.
• Prednisolone regimen: 50–60 mg once daily for 5 days followed by a 5‑day taper (total 10 days), or 25 mg twice daily for 10 days (moderate‑quality evidence) 15.
• Treatment must start within 72 hours; benefit after this window is markedly reduced and unclear (AAO‑HNS, moderate evidence) 14, 16, 15.
• Recovery rates with steroids: 83 % at 3 months vs 63.6 % with placebo (p < 0.001) and 94.4 % at 9 months vs 81.6 % with placebo (high‑quality evidence) 15.
• Steroids accelerate time to recovery compared with placebo (moderate evidence) 15.

Antiviral Therapy

• Antivirals alone provide no benefit over placebo and should not be used as monotherapy (AAO‑HNS, strong evidence) 14, 16, 15.
• Adding antivirals to steroids may be considered only for patients with complete or severe facial paralysis after shared decision‑making (moderate evidence) 14, 16.
• Combination therapy shows a modest, non‑significant trend: 96.5 % recovery with steroids + antivirals vs 89.7 % with steroids alone; larger trials found no significant difference (low‑moderate evidence) 14, 16.

Ocular Protection (Mandatory)

• Immediate eye protection is required for any patient with impaired eyelid closure to prevent corneal abrasion, exposure keratitis, ulceration, and permanent vision loss (AAO‑HNS, strong evidence) 14, 17.
• Artificial tears should be applied every 1–2 hours while awake (moderate evidence) 14.
• Lubricating ointment should be applied at bedtime (moderate evidence) 14.
• Eye patching or taping the eyelid closed during sleep is recommended (moderate evidence) 14.
• Sunglasses should be worn for outdoor protection (moderate evidence) 14.
• Patients should be instructed to monitor for burning, itching, eye irritation, vision changes, or pain (moderate evidence) 14.

Diagnostic Criteria (Diagnosis of Exclusion)

• Rapid onset (< 72 h) of unilateral facial weakness is a required feature (AAO‑HNS, moderate evidence) 17, 18.
• Absence of other neurologic abnormalities (no additional cranial‑nerve deficits or limb weakness) is required (moderate evidence) 17.
• Associated symptoms may include ipsilateral ear/facial pain, taste disturbance, hyperacusis, or dry eye/mouth (moderate evidence) 18.

Red‑Flag Findings Requiring Advanced Imaging

• Bilateral facial palsy or lack of recovery after 3 months warrants MRI of the facial‑nerve course with gadolinium (moderate evidence) 17.

Recommendations Against Routine Testing

• Routine laboratory tests are not indicated in typical Bell’s palsy (moderate evidence) 17.
• Routine imaging (CT/MRI) is not indicated in classic presentations (moderate evidence) 17.
• Electrodiagnostic testing (EMG/ENoG) is not indicated for patients with incomplete facial paralysis (moderate evidence) 14, 17.

Special Populations

Children (< 16 years)

• Evidence for steroid efficacy in children is inconclusive; no high‑quality controlled trials exist (low evidence) 16, 15.
• Spontaneous recovery rates are high (up to 94 %) (moderate evidence) 16, 15.
• Steroids may be considered after shared decision‑making with caregivers, given a favorable benefit‑harm balance (low‑moderate evidence) 16, 15.

Pregnant Women

• Steroid use should be discussed individually, weighing risks and benefits (moderate evidence) 14.

Interventions Not Recommended (Insufficient Evidence)

• Surgical facial‑nerve decompression – no recommendation due to insufficient evidence (low evidence) 17.
• Acupuncture – insufficient evidence to recommend (low evidence) 17.
• Physical therapy – no formal recommendation; may be considered in severe cases with incomplete recovery (low evidence) 17.

Follow‑Up and Referral Criteria

• Refer to a facial‑nerve specialist or reassess if new/worsening neurologic findings develop (moderate evidence) 17.
• Refer if new ocular symptoms appear (e.g., corneal irritation, decreased tear production, vision changes) (moderate evidence) 17.
• Refer if facial recovery remains incomplete at 3 months after onset (moderate evidence) 17.

Prognosis

• Without treatment: ~70 % of patients with complete paralysis recover fully within 6 months; up to 94 % with incomplete paralysis recover spontaneously (moderate evidence) 17, 18.
• With treatment: most patients improve within 2–3 weeks and achieve complete recovery by 3–4 months (moderate evidence) 17, 18.

Common Pitfalls to Avoid

• Missing the 72‑hour treatment window – counsel patients to seek immediate care for facial weakness (strong evidence) 14, 16, 15.
• Prescribing antivirals alone – ineffective and wastes the critical treatment window (strong evidence) 14, 16.
• Neglecting eye protection – can lead to rapid corneal injury and permanent vision loss (strong evidence) 14, 17.
• Over‑testing typical presentations – routine labs and imaging add cost without benefit (moderate evidence) 17.

Corticosteroid Therapy for Acute Bell’s Palsy

Indications & Timing

• All patients ≥ 16 years with acute Bell’s palsy should receive oral corticosteroids within 72 hours of symptom onset; this is the only treatment with strong evidence for improving facial‑nerve recovery and reducing long‑term disability. [19][20]

Recommended Steroid Regimens

• Prescribe prednisolone 50–60 mg once daily for 5 days, then taper over 5 days (total 10‑day course), or prednisolone 25 mg twice daily for 10 days. [19][21]

Efficacy Outcomes

• Recovery at 3 months: 83 % with steroids vs 63.6 % with placebo (p < 0.001).
• Recovery at 9 months: 94.4 % with steroids vs 81.6 % with placebo. Both differences are statistically significant, demonstrating that steroids markedly increase the likelihood of full facial‑nerve recovery. [19][20]
• Steroids significantly shorten time to recovery compared with placebo. 19

Antiviral Therapy (Adjunct)

• Antivirals alone provide no benefit over placebo and should not be used as monotherapy. 21
• Adding antivirals to steroids may be considered only for patients with complete or severe facial paralysis after shared decision‑making; a single trial reported 96.5 % recovery with combination therapy vs 89.7 % with steroids alone, but larger trials have shown no significant advantage. 21

Eye Protection (Mandatory for Lagophthalmos)

• For any patient with impaired eyelid closure, tape or patch the eyelid closed during sleep to prevent corneal injury. 19

Diagnostic Approach – When NOT to Test

• In typical presentations, routine laboratory tests, CT/MRI, and electrodiagnostic studies (EMG/ENoG) are not indicated, as they add cost without improving outcomes. 19

Red‑Flag Findings Requiring Advanced Imaging

*If MRI is contraindicated, obtain a contrast‑enhanced CT. [19][20]

Special Population: Children (< 16 years)

• Evidence for steroid efficacy in children is inconclusive; no high‑quality controlled trials exist, and spontaneous recovery rates are high (≈ 94 %). 21
• Steroids may be considered after shared decision‑making with caregivers, given a favorable benefit‑harm profile and presumed similar pathophysiology to adults. 21

Follow‑Up & Referral Criteria

• Re‑evaluate or refer to a facial‑nerve specialist if facial recovery remains incomplete at 3 months post‑onset. 19

Critical Pitfalls to Avoid

• Missing the 72‑hour treatment window—prompt counseling for immediate care is essential. 19
• Prescribing antivirals alone—ineffective and delays appropriate steroid therapy. 21
• Neglecting eye protection in patients with lagophthalmos—risk of corneal injury and permanent vision loss. 19
• Over‑testing typical cases with routine labs or imaging—wastes resources without improving outcomes. 19

Evidence‑Based Recommendations for Bell’s Palsy Management

Combination Antiviral Therapy (Optional Adjunct)

• In patients with severe facial paralysis, clinicians may consider adding an oral antiviral to corticosteroid therapy after shared decision‑making; this approach is endorsed by the American Academy of Otolaryngology‑Head and Neck Surgery. 22
• A randomized trial reported a recovery rate of ≈96 % with steroids + antivirals versus ≈90 % with steroids alone in severe cases, indicating a modest absolute benefit of less than 7 %. The same study also noted a potential reduction in long‑term synkinesis (relative risk 0.56). [22][23]

Eye Protection for Lagophthalmos

• Immediate eye protection (artificial tears, lubricating ointment, eyelid taping or patching during sleep, and sunglasses outdoors) is recommended for any patient with impaired eyelid closure to prevent corneal abrasion, exposure keratitis, ulceration, and permanent vision loss; this recommendation follows guidance from the American Academy of Otolaryngology‑Head and Neck Surgery. 22
• Patients should be instructed to monitor for ocular burning, itching, irritation, visual changes, or pain and to seek prompt ophthalmologic evaluation if these occur. 22

Electrodiagnostic Testing (EMG/ENoG)

• Routine electrodiagnostic studies are not recommended for typical Bell’s palsy presentations; they add cost without improving outcomes. 22
• EMG/ENoG may be performed only in cases of complete facial paralysis to aid prognostication, but should be avoided in incomplete paralysis. This selective use is supported by the American Academy of Otolaryngology‑Head and Neck Surgery. 22

Special Populations

Pregnancy

• Steroid therapy should be individualized for pregnant patients, weighing maternal and fetal risks and benefits; treatment decisions are to be made on a case‑by‑case basis per American Academy of Otolaryngology‑Head and Neck Surgery guidance. 22

Diabetes, Morbid Obesity, or Steroid Intolerance

• In patients with significant comorbidities that limit steroid use (e.g., uncontrolled diabetes, severe obesity, or known steroid intolerance), alternative management strategies should be considered, as recommended by the American Academy of Otolaryngology‑Head and Neck Surgery. 22

Evidence‑Based Management of Bell’s Palsy

Timing of Steroid Initiation

• Initiating corticosteroid therapy within 72 hours of facial‑weakness onset markedly improves outcomes, whereas treatment started after this window shows substantially reduced and uncertain efficacy. – American Academy of Otolaryngology‑Head and Neck Surgery 24, 25

Antiviral Therapy

• Antiviral agents alone are ineffective and should not be used as monotherapy for Bell’s palsy. – American Academy of Otolaryngology‑Head and Neck Surgery 24, 25

High‑Dose Steroid Considerations

High‑dose corticosteroids (≥80 mg/day) significantly lower the risk of non‑recovery at 6 months, but the evidence is limited by serious risk‑of‑bias concerns; current guidelines do not yet endorse this regimen. – American Academy of Otolaryngology‑Head and Neck Surgery 24, 25

Clinical Pitfalls

• Missing the 72‑hour treatment window leads to a drastic reduction in therapeutic benefit; clinicians must counsel patients with acute facial weakness to seek care immediately. – American Academy of Otolaryngology‑Head and Neck Surgery 24, 25
• Prescribing antivirals without steroids provides no benefit and wastes the critical treatment window. – American Academy of Otolaryngology‑Head and Neck Surgery 24, 25
• Routine laboratory tests, imaging, and electrodiagnostic studies in classic Bell’s palsy add cost without improving outcomes and should be avoided. – American Academy of Otolaryngology‑Head and Neck Surgery 24, 25

Referral and Reassessment Criteria

• Refer to a facial‑nerve specialist if new or worsening neurologic findings develop at any time. – American Academy of Otolaryngology‑Head and Neck Surgery 24, 25
• Refer if new ocular symptoms appear (e.g., corneal irritation, decreased tear production, vision changes). – American Academy of Otolaryngology‑Head and Neck Surgery 24, 25
• Refer if incomplete facial recovery persists at 3 months after onset. – American Academy of Otolaryngology‑Head and Neck Surgery 24, 25

Imaging Red‑Flag Indicators

• Obtain immediate MRI with gadolinium for any of the following, as they suggest alternative diagnoses:

Evidence‑Based Management of Bell’s Palsy

Antiviral Therapy

• Antiviral monotherapy provides no benefit over placebo and should be avoided, as it wastes the critical treatment window for acute facial nerve palsy. (American Academy of Otolaryngology‑Head and Neck Surgery) 26

Diagnostic Testing – Routine Evaluations Not Indicated

• In patients with classic acute unilateral facial weakness, routine laboratory tests (e.g., Lyme serology, CBC, metabolic panel) are not recommended because they do not improve diagnostic accuracy or outcomes. (American Academy of Otolaryngology‑Head and Neck Surgery) 26
• Routine neuroimaging (CT or MRI) is unnecessary in straightforward cases of Bell’s palsy, as imaging does not alter management in the absence of atypical features. (American Academy of Otolaryngology‑Head and Neck Surgery) 26
• Electrodiagnostic studies (EMG/ENoG) should not be performed in patients with incomplete facial paralysis, since they add cost without demonstrable benefit to recovery. (American Academy of Otolaryngology‑Head and Neck Surgery) 26

Red‑Flag Findings Requiring Advanced Imaging

• Presence of bilateral facial palsy warrants immediate MRI of the facial nerve pathway with gadolinium to exclude alternative etiologies. (American Academy of Otolaryngology‑Head and Neck Surgery) 26
• Additional cranial nerve deficits accompanying facial weakness also require urgent MRI with gadolinium to investigate possible brainstem pathology, tumor, or infectious causes. (American Academy of Otolaryngology‑Head and Neck Surgery) 26

Interventions Not Recommended (Insufficient Evidence)

• Surgical decompression of the facial nerve cannot be recommended because high‑quality evidence supporting its efficacy is lacking. (American Academy of Otolaryngology‑Head and Neck Surgery) 26
• Acupuncture lacks sufficient evidence to support its use in Bell’s palsy management. (American Academy of Otolaryngology‑Head and Neck Surgery) 26
• Routine physical therapy is not formally endorsed; while it may be considered for severe or incompletely recovered cases, robust data demonstrating benefit are absent. (American Academy of Otolaryngology‑Head and Neck Surgery) 26

Diagnostic Criteria and Red‑Flag Evaluation for Bell’s Palsy

Diagnosis (American Academy of Otolaryngology‑Head and Neck Surgery)

• Bell’s palsy is a diagnosis of exclusion defined by rapid onset (< 72 h) of unilateral facial weakness that includes the forehead, absence of other neurologic deficits, and possible associated ipsilateral ear pain, taste disturbance, hyperacusis, or dry eye/mouth. Strength of evidence: consensus guideline (moderate). 27

Red‑Flag Findings Prompting MRI with Gadolinium (American Academy of Otolaryngology‑Head and Neck Surgery)

• Immediate contrast‑enhanced MRI of the facial nerve is recommended when any of the following are present: bilateral facial palsy, isolated branch paralysis sparing the forehead, additional cranial nerve deficits, recent temporal‑bone trauma or known tumor, or lack of recovery after 3 months. Strength of evidence: guideline recommendation (strong). 27

Interventions Lacking Sufficient Evidence

• Surgical facial‑nerve decompression is not recommended for routine use because high‑quality evidence supporting benefit is lacking. Strength of evidence: insufficient (low). 28

• Acupuncture does not have adequate evidence to support its use in Bell’s palsy. Strength of evidence: insufficient (low). 28

• Physical therapy may be considered for patients with severe paralysis or incomplete recovery at 3 months, but formal recommendation is absent due to limited high‑quality data. Strength of evidence: limited (low). 28

Differential Diagnosis – Stroke vs. Bell’s Palsy (American Academy of Otolaryngology‑Head and Neck Surgery)

• In Bell’s palsy the forehead is involved (patient cannot wrinkle the forehead on the affected side), whereas stroke typically spares the forehead because of bilateral cortical innervation of the upper face. Recognizing this distinction helps avoid misdiagnosis. Strength of evidence: guideline consensus (moderate). 27

Management of Bell’s Palsy in Pregnancy – Evidence‑Based Recommendations

Corticosteroid Therapy

• Initiate oral corticosteroids within 72 hours of symptom onset in pregnant patients. The efficacy demonstrated in non‑pregnant adults is considered applicable to pregnancy, and the benefit of preventing permanent facial‑nerve damage outweighs the minimal fetal risk from a short prednisolone course. American Academy of Otolaryngology–Head and Neck Surgery 29 – high‑quality adult RCT evidence extrapolated to pregnancy.

Guideline Statements

• Corticosteroids remain the cornerstone of treatment for Bell’s palsy in pregnancy. The American Academy of Otolaryngology–Head and Neck Surgery advises that steroid therapy should not be withheld because of pregnancy, and that any decision to add antiviral agents be individualized. American Academy of Otolaryngology–Head and Neck Surgery 29 – strong (Class I) recommendation.

Antiviral Considerations

• Antiviral agents may be added only for severe or complete facial paralysis after shared decision‑making. One randomized trial reported a recovery rate of 96.5 % with combination therapy versus 89.7 % with steroids alone, an absolute benefit of 6.8 %. American Academy of Otolaryngology–Head and Neck Surgery 29 – moderate‑quality evidence from a single trial.
• In pregnancy, the modest benefit of antivirals must be weighed against potential fetal drug exposure. Overall, evidence supporting antiviral efficacy is weak even in non‑pregnant populations. American Academy of Otolaryngology–Head and Neck Surgery 29 – low‑to‑moderate quality evidence, limited data.

Management of Bell’s Palsy in Adults

Pharmacologic Treatment

• Oral corticosteroids should be started within 72 hours of symptom onset in all patients ≥ 16 years – this is the only therapy with strong evidence for improving facial‑nerve recovery and reducing long‑term disability (AAO‑HNS). Strong evidence. 30
• Prednisolone regimen: 50–60 mg once daily for 5 days then taper over the next 5 days (total 10‑day course) or 25 mg twice daily for 10 days (AAO‑HNS). Strong evidence. 30
• Recovery with steroids: 83 % achieve complete recovery at 3 months versus 63.6 % with placebo (p < 0.001). Strong evidence. 30
• Recovery at 9 months: 94.4 % complete recovery with steroids versus 81.6 % with placebo. Strong evidence. 30
• Time to recovery is significantly shorter with steroids compared with placebo. Strong evidence. 30
• The 72‑hour window is critical – initiating therapy after this period markedly reduces efficacy and introduces uncertainty. Strong evidence. 30
• Antiviral monotherapy is contraindicated because it provides no benefit over placebo and wastes the critical treatment window (AAO‑HNS). Strong evidence of no benefit. 30
• Adding antivirals to steroids may be considered only for severe or complete paralysis after shared decision‑making; the incremental benefit is modest (≈ 6.8 % absolute improvement) and not statistically significant in larger trials. Low‑quality evidence. 30

Diagnostic Criteria & Imaging

• Clinical diagnosis requires rapid onset (< 72 h) of unilateral facial weakness that includes the forehead (inability to wrinkle the affected side), with no other neurologic deficits (AAO‑HNS). Strong evidence. [31][32]

• Red‑flag findings that mandate contrast‑enhanced MRI of the facial nerve (AAO‑HNS):

All red‑flag actions are supported by AAO‑HNS evidence. 30

If MRI is contraindicated, obtain a contrast‑enhanced CT scan (AAO‑HNS). *Moderate evidence**. 30

Interventions Lacking Sufficient Evidence

• Surgical facial‑nerve decompression – insufficient high‑quality data; no recommendation can be made (AAO‑HNS). Insufficient evidence. [31][32]
• Acupuncture – evidence is inadequate to support routine use (AAO‑HNS). Insufficient evidence. [31][32]
• Physical therapy – no formal recommendation due to lack of high‑quality trials; may be considered in severe cases with incomplete recovery at 3 months (AAO‑HNS). Insufficient evidence. [31][32]

Follow‑Up and Referral Criteria

• Refer to a facial‑nerve specialist or reassess if any of the following occur (AAO‑HNS):
  
  • New or worsening neurologic findings at any time.
  • Development of new ocular symptoms (e.g., corneal irritation, decreased tear production, vision changes, pain).
  • Incomplete facial recovery at 3 months after onset.

These criteria are based on AAO‑HNS guidance. *Moderate evidence**. 31

Critical Pitfalls to Avoid

• Missing the 72‑hour treatment window – delayed therapy shows markedly reduced efficacy (AAO‑HNS). Strong evidence. 30
• Prescribing antivirals alone – ineffective and diverts attention from essential steroid therapy (AAO‑HNS). Strong evidence of no benefit. 30

Evidence‑Based Management of Bell’s Palsy (AAO‑HNS)

Primary Pharmacologic Therapy

• Oral corticosteroids should be started for every patient ≥ 16 years within 72 hours of symptom onset. The American Academy of Otolaryngology–Head and Neck Surgery (AAO‑HNS) cites robust randomized‑controlled trial data showing a clear benefit in facial‑nerve recovery. Strong recommendation (high‑quality evidence). 33

Timing of Intervention

• Therapy initiated after the 72‑hour window yields markedly reduced efficacy and uncertain benefit. The same AAO‑HNS guideline emphasizes that early treatment is critical for optimal outcomes. Strong recommendation (high‑quality evidence). 33

Antiviral Monotherapy

• Acyclovir (or any antiviral) given alone provides no advantage over placebo and should never be prescribed. The BELLS trial (n ≈ 500) demonstrated identical 3‑month recovery rates (≈ 63 % vs ≈ 65 %). Strong recommendation (high‑quality evidence). 33

Red‑Flag Findings Requiring Immediate MRI with Gadolinium

The AAO‑HNS advises urgent contrast‑enhanced MRI when any of these signs are present.* Moderate recommendation (based on expert consensus and limited data). 33

Follow‑up and Referral Criteria

• Any new or worsening neurologic symptom at any time warrants reassessment or referral to a facial‑nerve specialist. This guidance is part of the AAO‑HNS practice statement. Moderate recommendation (expert consensus). 33